University of Alabama at Birmingham, Obstetrics and Gynecology, 10390 Women and Infants Center, Birmingham, AL 35249-7333, United States.
Mol Cell Endocrinol. 2013 Jul 5;373(1-2):91-7. doi: 10.1016/j.mce.2012.10.029. Epub 2012 Dec 20.
Polycystic Ovarian Syndrome (PCOS) has been associated with numerous reproductive and metabolic abnormalities. Despite tremendous advances in the management of reproductive dysfunction, insight into the metabolic implications of PCOS is limited by the lack of uniform diagnostic criteria, the heterogeneity of the condition and the presence of confounders including obesity. Obesity clearly has a role in long term health and may best predict both reproductive and metabolic dysfunction as well as negatively affect the response to treatment in women with PCOS. Diabetes, cardiovascular disease and cancer are also at the forefront of any risk assessment or comprehensive treatment strategy for these women. Lifestyle modifications including dietary changes, increased exercise and weight loss are appropriate first line interventions for many women with PCOS. Pharmaceuticals including metformin, lipid lowering agents and oral contraceptives should be tailored to the individual's risk profile and treatment goals.
多囊卵巢综合征（PCOS）与许多生殖和代谢异常有关。尽管在生殖功能障碍的治疗方面取得了巨大进展，但由于缺乏统一的诊断标准、该病症的异质性以及包括肥胖症在内的混杂因素的存在，对 PCOS 的代谢影响的了解受到限制。肥胖症显然对长期健康有影响，并且可能是预测 PCOS 妇女生殖和代谢功能障碍的最佳因素，也会对治疗反应产生负面影响。糖尿病、心血管疾病和癌症也是这些女性风险评估或综合治疗策略的重点。对于许多患有 PCOS 的女性，包括饮食改变、增加运动和减肥在内的生活方式改变是合适的一线干预措施。二甲双胍、降脂药和口服避孕药等药物应根据个体的风险状况和治疗目标进行调整。
